These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

283 related items for PubMed ID: 8307114

  • 1. Increased serum neopterin levels in patients with Graves' disease.
    Wagner R, Hayatghebi S, Rosenkranz M, Reinwein D.
    Exp Clin Endocrinol; 1993; 101(4):249-54. PubMed ID: 8307114
    [Abstract] [Full Text] [Related]

  • 2. Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy.
    Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Barani L, Ferrannini E, Serio M.
    Clin Endocrinol (Oxf); 2006 Feb; 64(2):189-95. PubMed ID: 16430719
    [Abstract] [Full Text] [Related]

  • 3. Serum levels of the interferon-gamma-inducible alpha chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy.
    Antonelli A, Fallahi P, Rotondi M, Ferrari SM, Serio M, Miccoli P.
    Br J Surg; 2006 Oct; 93(10):1226-31. PubMed ID: 16838393
    [Abstract] [Full Text] [Related]

  • 4. Thyroid hormone modulates insulin-like growth factor-I(IGF-I) and IGF-binding protein-3, without mediation by growth hormone, in patients with autoimmune thyroid diseases.
    Inukai T, Takanashi K, Takebayashi K, Fujiwara Y, Tayama K, Takemura Y.
    Horm Metab Res; 1999 Oct; 31(10):576-9. PubMed ID: 10596968
    [Abstract] [Full Text] [Related]

  • 5. A preliminary clinical application of sICAM-1 RIA in three kinds of thyroid disease.
    Lu M, Fang P, Zhang Z, He H, Gao S, Hou B, Zheng R, Xiao Q, Yang L.
    Chin Med J (Engl); 2002 Oct; 115(10):1552-5. PubMed ID: 12490109
    [Abstract] [Full Text] [Related]

  • 6. Decreased nerve growth factor levels in hyperthyroid Graves' ophthalmopathy highlighting the role of neuroprotective factor in autoimmune thyroid diseases.
    Molnár I, Bokk A.
    Cytokine; 2006 Aug; 35(3-4):109-14. PubMed ID: 17008110
    [Abstract] [Full Text] [Related]

  • 7. Endothelin-1 levels in patients with disorders of the thyroid gland.
    Tilly N, Schneider JG, Leidig-Bruckner G, Sommer U, Kasperk C.
    Exp Clin Endocrinol Diabetes; 2003 Apr; 111(2):80-4. PubMed ID: 12746758
    [Abstract] [Full Text] [Related]

  • 8. [Impact of serum thyroglobulin concentration in the diagnosis of benign and malignant thyroid diseases].
    Rink T, Dembowski W, Schroth HJ, Klinger K.
    Nuklearmedizin; 2000 Aug; 39(5):133-8. PubMed ID: 10984889
    [Abstract] [Full Text] [Related]

  • 9. Decrease of peripheral large granular lymphocytes in Graves' disease.
    Iwatani Y, Amino N, Kabutomori O, Mori H, Tamaki H, Motoi S, Izumiguchi Y, Miyai K.
    Clin Exp Immunol; 1984 Jan; 55(1):239-44. PubMed ID: 6546360
    [Abstract] [Full Text] [Related]

  • 10. Serum CD40/CD40L system in Graves' disease and Hashimoto's thyroiditis related to soluble Fas, FasL and humoral markers of autoimmune response.
    Mysliwiec J, Oklota M, Nikolajuk A, Waligorski D, Gorska M.
    Immunol Invest; 2007 Jan; 36(3):247-57. PubMed ID: 17558708
    [Abstract] [Full Text] [Related]

  • 11. Serum immunoglobulin E and soluble CD23 in patients with Graves' disease.
    Sayinalp S, Akalin S, Sayinalp N, Erbaş T, Bayraktar M, Ozcebe OI, Dündar S, Kirazli S.
    Horm Metab Res; 1996 Mar; 28(3):133-7. PubMed ID: 8926012
    [Abstract] [Full Text] [Related]

  • 12. Are serum neopterin concentrations superior to other parameters in the differential diagnosis and prognostic assessment of Graves' disease?
    Schomburg A, Grünwald F, Schultes B, Hotze A, Bender H, Biersack HJ.
    Exp Clin Endocrinol Diabetes; 1996 Mar; 104(2):123-9. PubMed ID: 8740935
    [Abstract] [Full Text] [Related]

  • 13. [Thyroid antibodies and their diagnostic value].
    Schneidinger P, Joller-Jemelka H, Grob PJ.
    Schweiz Med Wochenschr; 1985 Nov 02; 115(44):1536-44. PubMed ID: 3841229
    [Abstract] [Full Text] [Related]

  • 14. Serum IL-18 levels are not increased in patients with untreated Graves' ophthalmopathy.
    Wakelkamp IM, Prummel MF, Wiersinga WM.
    Horm Metab Res; 2004 Jan 02; 36(1):44-7. PubMed ID: 14983406
    [Abstract] [Full Text] [Related]

  • 15. Sensitive thyroid-stimulating antibody assay with high concentrations of polyethylene glycol for the diagnosis of Graves' disease.
    Takasu N, Kamijo K, Sato Y, Yoshimura H, Nagata A, Ochi Y.
    Clin Exp Pharmacol Physiol; 2004 Jan 02; 31(5-6):314-9. PubMed ID: 15191404
    [Abstract] [Full Text] [Related]

  • 16. Thyrotropin binding inhibiting immunoglobulins (TBII) in Graves' disease, toxic nodular goitre and autoimmune thyroiditis.
    Wägar G, Mäkinen T, Lamberg BA, Gordin A, Apter L, Pekonen F.
    Ann Clin Res; 1982 Apr 02; 14(2):83-9. PubMed ID: 6184007
    [Abstract] [Full Text] [Related]

  • 17. Circulating chemokines in patients with autoimmune thyroid diseases.
    Domberg J, Liu C, Papewalis C, Pfleger C, Xu K, Willenberg HS, Hermsen D, Scherbaum WA, Schloot NC, Schott M.
    Horm Metab Res; 2008 Jun 02; 40(6):416-21. PubMed ID: 18415893
    [Abstract] [Full Text] [Related]

  • 18. Serum cytokines levels in Graves' disease.
    Al-Humaidi MA.
    Saudi Med J; 2000 Jul 02; 21(7):639-44. PubMed ID: 11500727
    [Abstract] [Full Text] [Related]

  • 19. Soluble intercellular adhesion molecule-1 (sICAM-1) in Graves' disease.
    Balázs C, Kiss E.
    Acta Microbiol Immunol Hung; 1994 Jul 02; 41(4):451-6. PubMed ID: 7866729
    [Abstract] [Full Text] [Related]

  • 20. Soluble Fas, Fas ligand and Bcl-2 in autoimmune thyroid diseases: relation to humoral immune response markers.
    Myśliwiec J, Okota M, Nikołajuk A, Górska M.
    Adv Med Sci; 2006 Jul 02; 51():119-22. PubMed ID: 17357290
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.